OMB APPROVAL

OMB Number:

   3235-0167

Expires:

   November 30, 2010

Estimated average burden

hours per response

   1.50

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 15

 

Certification and Notice of Termination of Registration under Section 12(g) of the

Securities Exchange Act of 1934 or Suspension of Duty to File Reports Under Sections 13

and 15(d) of the Securities Exchange Act of 1934

 

Commission File Number 001-13341

 

 

 

Titan Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080 (650) 244-4990

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

 

Common Stock

(Title of each class of securities covered by this Form)

 

 

N/A

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)   x    Rule 12h-3(b)(1)(ii)   ¨
Rule 12g-4(a)(2)   ¨    Rule 15d-6   ¨
Rule 12h-3(b)(1)(i)   ¨     

Approximate number of holders of record as of the certification or notice date: 143

Pursuant to the requirements of the Securities Exchange Act of 1934 Titan Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date:  

December 15, 2008

   By:   /s/ Robert Farrell
      Robert Farrell, Chief Financial Officer

Instruction: This form is required by Rules 12g-4, 12-h-3 and 15d-6 of the General Rules and Regulations under the Securities Exchange Act of 1934. The registrant shall file with the Commission three copies of Form 15, one of which shall be manually signed. It may be signed by an officer of the registrant, by counsel or by any other duly authorized person. The name and title of the person signing the firm shall be typed or printed under the signature.

 

SEC2069(02-08)   Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.